Palvella Therapeutics has priced an upsized public offering of 1.6 million shares at $125 per share, generating $200 million in gross proceeds. The clinical-stage biopharmaceutical company expanded the initial offering size to capitalize on investor demand for its rare disease pipeline. The transaction is scheduled to close on February 27, 2026, subject to customary closing conditions.
The company intends to deploy the capital toward advancing its lead therapeutic programs, including QTORIN rapamycin and QTORIN pitavastatin, which are in clinical development for rare skin diseases and vascular malformations. These conditions represent significant unmet medical needs with limited treatment options currently available to patients. The funding will support ongoing clinical trials and regulatory advancement of these candidates.
Palvella's offering underscores continued investor interest in specialized pharmaceutical companies focused on rare and orphan diseases. The pricing and expansion of the offering reflect market confidence in the company's clinical pipeline and development strategy. Goldman Sachs and Jefferies are serving as lead underwriters for the transaction.